Detalhe da pesquisa
1.
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
Purinergic Signal
; 19(3): 513-522, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781824
2.
A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model.
Andrologia
; 54(9): e14498, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732294
3.
Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
Molecules
; 27(12)2022 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35744805
4.
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
J Drugs Dermatol
; 15(8): 931-8, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537992
5.
A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.
Mediators Inflamm
; 2014: 708746, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25374446
6.
Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
Biomedicines
; 12(4)2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38672201
7.
A longterm complete response to namodenoson in liver cancer with ChildPugh B cirrhosis: A case report.
Exp Ther Med
; 27(6): 263, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38756903
8.
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Oncologist
; 18(1): 25-6, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23299770
9.
Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/ß-catenin, NF-κB, and RAS Signaling Pathways.
Biomolecules
; 13(11)2023 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38002266
10.
Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine.
Purinergic Signal
; 7(4): 453-62, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21720785
11.
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
Aliment Pharmacol Ther
; 54(11-12): 1405-1415, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671996
12.
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
Cancers (Basel)
; 13(2)2021 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33430312
13.
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Ophthalmology
; 117(7): 1287-93, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20304499
14.
Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.
Drug Des Devel Ther
; 13: 491-497, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30787591
15.
The A3 adenosine receptor agonist, namodenoson, ameliorates nonalcoholic steatohepatitis in mice.
Int J Mol Med
; 44(6): 2256-2264, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31638172
16.
Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.
J Immunol Res
; 2018: 2310970, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29862305
17.
Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply.
Aliment Pharmacol Ther
; 55(4): 485-486, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35092054
18.
The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
Clin Rheumatol
; 35(9): 2359-62, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26886128
19.
A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy.
Mol Med Rep
; 14(5): 4335-4341, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27666664
20.
Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.
Oncogene
; 21(25): 4060-4, 2002 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-12037688